Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shore Capital returns AB Foods to 'buy' despite H1 disappointment

(Sharecast News) - Shore Capital has returned Associated British Foods to a 'buy' rating after a period of review, applauding the company for tacking action to improve problem areas within the business. The broker had placed the retail and food conglomerate under review following its first-half results in late-April, in which it reported that revenues fell 2% and adjusted pre-tax profit slumped 10%.

Shore Capital highlighted some areas of "robust progress", more than offset by a number of disappointments, including within UK bread (Allied Bakeries), Spanish sugar (Azucarera) and bioethanol (Vivergo).

"Post the update, we cut FY25F pre-tax profit and adjusted EPS by 5.8% to £1.684bn and 173.5p, far from ideal, which caused us to pause and reflect on the bull case," the broker said in a research note.

"However, after a period of reflection, we see more to like than not in ABF's medium to long-term investment thesis, with high-quality assets, a very strong balance sheet, a multitude of growth opportunities and a building record of shareholder-friendly capital allocation."

Shore Capital said that AB Foods is "now more assertively dealing with current problems (on the whole).

The stock has fallen by around 9% since the interim results were announced on 29 April, but trading at a EV/EBITDA multiple of 7.2 and a price-to-earnings multiple of 12.0, falling to 5.9 and 9.6 for the fiscal year ending September 2027.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.